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Methotrexate Induced Accelerated Nodulosis
V Agarwal, Amita Aggarwal, R Misra
Abstract
Methotrexate induced accelerated nodulosis (MIAN) is a rare but unique side effect of methotrexate
therapy. There is paucity of data from our country about this entity. We analyzed 14 cases of MIAN
and studied its association with gender, rheumatoid factor positivity and dose and duration of
methotrexate. Fourteen patients (8 females), 12 with rheumatoid arthritis (8 seropositive), one each
with juvenile idiopathic (JIA) and psoriatic arthritis (PsA) were detected to have MIAN during study
period. All the patients presented with acute onset of multiple nodules. Radial border of fingers was the
most commonly involved site. Disease was inactive in all but two patients at the time of appearance of
MIAN. There was no association of MIAN with gender, rheumatoid factor positivity, disease duration,
cumulative dose and duration of methotrexate therapy. Two patients each were treated with colchicine,
D-penicillamine or hydroxy-chloroquine for 3-6 months without any response. We conclude that
MIAN is a benign side effect of methotrexate treatment. ©
Department of Clinical Immunology, Sanjay Gandhi Postgraduate
Institute of Medical Sciences, Lucknow, India.
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INTRODUCTION
Methotrexate, the most common disease modifying drugused in patients with rheumatoid arthritis (RA), has
been associated with a rare, but unique side effect i.e.
methotrexate induced accelerated nodulosis (MIAN). The
prevalence rate of MIAN varies between 8-11 % in different
series.1,2 Typically, it presents as acute onset, multiple, small,
painless or painful nodules over fingers and pulp spaces.
Unusually, however, involvement of  helix of ear, sole of feet,
penis, meninges, scalp, chest, heart, surgical incisions  and
lungs has also been reported.2 MIAN is associated with HLA
DR B1 *0401 in Caucasians.2,3  A total of 58 cases of MIAN
have been reported in the English language literature till the
year 2001.4 Only one case of MIAN has been reported from
India so far.5 The reason for paucity of reports on MIAN from
our country could be related to lack of awareness, low
incidence or under-reporting. We looked for the presence of
MIAN in patients receiving methotrexate for various
rheumatological conditions at our centre.
MATERIAL AND METHODS
From January 1997 to December 2000 about 700 patients
receiving methotrexate for various rheumatological conditions
at the out-patient clinic of department of Clinical Immunology
at Sanjay Gandhi Postgraduate Institute of Medical Sciences,
Lucknow were screened for MIAN.
The association of MIAN with gender, rheumatoid factor
seropositivity, disease activity, extra articular manifestations,
dose and duration of methotrexate therapy, and its response
to hydroxychloroquine, D-penicillamine and colchicine were
analyzed. The disease activity was assessed by the physician
based on tender joint count, swollen joint count, duration of
early morning stiffness, ESR and patients were categorized
as having active or inactive disease.
RESULTS
Fourteen patients (8 females), 12 with rheumatoid arthritis
(RA), one each with juvenile idiopathic (JIA) and psoriatic
arthritis (PsA) were detected to have MIAN (Table 1). The
mean age, disease duration, cumulative dose of methotrexate
and duration of methotrexate treatment were 44.7 years (range
6.5 -58 years), 83.57 months (range 12-204 months), 691.2 mg
(range 60-2400) and 23.07 months (range 4-60 months)
respectively. Of the twelve patients with RA eight were
seropositive, none had extra-articular manifestations. None
of the patients had pulmonary nodules on chest radiographs.
In all the cases, multiple nodules erupted acutely with size
varying from 0.3 to 2 cm. Nodules were painless in all but four
cases. The various sites of involvement by MIAN were; radial
border of fingers (n=11; Fig.), elbow (n=5),
metatarsophalangeal joints (n=4), dorsum of hands (n= 3),
dorsum of feet (n=2), and one each on palms and soles,
tendoachilles and shin.
Twelve patients had inactive disease at the time of
appearance of MIAN. Two patients each were treated with,
colchicine, D-penicillamine and hydroxychloroquine in
addition to methotrexate for 3-6 months but did not have any
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regression of nodules. Four patients, however, had
spontaneous disappearance of nodules on continuation of
same dose of methotrexate, whereas in two patients nodules
disappeared on reducing the dose of methotrexate by 2.5 mg
per week. Rest of the patients continued to have persistent
nodulosis. Three patients had episodic nodulosis with
resolution.
Histopathology done of nodule from left index finger in
patient number five showed central zone of necrosis encircled
by palisading macrophages and multinucleated giant cells,
features  consistent with rheumatoid nodule. HLA typing
available for patient number 1 and 9 did not reveal presence
HLA DR 04.
DISCUSSION
Our study reveals that MIAN is not uncommon in India.
Rheumatoid nodule and MIAN may be difficult to differentiate,
but acute onset of multiple nodules, atypical site of
involvement especially over the fingers, seronegative status,
quiescent arthritis and absence of extra-articular
manifestations, suggest MIAN whereas rheumatoid nodules
are classically detected in patients with severe active disease
with extra-articular manifestations.  Our findings are in
agreement with the literature.1,2
Lack of efficacy of hydroxychloroquine, D- penicillamine
and colchicine in our study is in contrast to earlier reports.3,5,6
We used these agents for a short period, which may not be
adequate as reported earlier.3 There is no consensus regarding
the various therapeutic options; discontinuation of
Table 1
Pt. Age Sex Diagnosis MIAN Duration of Cumulative dose RF Drugs for MIAN Outcome Arthritis Past h/o
MTX (months) of MTX (mg) (12 months) nodules
1 46 M RA Painless 12 480 + None Spontaneous Active No
recovery
2 48 F RA Painful 30 900 — HCQ No response Inactive Yes, One
previous
episode
3 58 M RA Painful 24 1030 + Colchicine No response Inactive No
4 55 F RA Painful 11 330 + Colchicine Partial Inactive No
response
5 36 F RA Painful 60 2400 + HCQ Partial Inactive Yes,  Two
response episode,
self limiting
6 42 F RA Painless 30 1200 — None Spontaneous Inactive No
recovery
7 43 F RA Painless 5 150 + None Spontaneous Inactive No
recovery
8 32 F RA Painless 5 150 + None Spontaneous Inactive No
recovery
9 44 F RA Painless 24 960 + None Spontaneous Inactive No
recovery
10 41 M RA Painless 36 1440 — D-Pen Persisting Inactive Yes, One
episode,
self limiting
11 6.5 M JIA Painless 16 160 — None Persisting Inactive No
12 40 M PsA Painless 6 240 — None Recovered, Active No
MTX stop
13 51 M RA Painless 4 60 — D-Pen Persisting Inactive No
14 41 F RA Painless 60 360 + None Spontaneous Inactive No
recovery
JIA: Juvenile idiopathic arthritis; PsA: psoriatic arthritis
Fig. 1 : Photograph of hand showing small nodule on the border of the
fingers in a patient with MIAN
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methotrexate, addition of additional antirheumatic drugs while
continuing methotrexate or observation alone while
continuing the methotrexate. Ahmed et al have reported
protective efficacy of hydroxychloroquine in patients of RA
with HLA DR  B1*0401 allele. Based on the postulated
mechanism of formation of MIAN, role of adenosine A1
receptor blockers seems interesting.
Four of the patients had spontaneous recovery of MIAN
despite continuation of methotrexate. These patients are
unlikely to have rheumatoid nodules as they all had acute
onset, atypical sites of involvement, inactive arthritis (both
clinically and serologically) and absence of extra-articular
manifestations. In addition, two of these patients were
seronegative for rheumatoid factor. The reasons for the
spontaneous resolution of MIAN despite continuation of
methotrexate need further study.
How do these nodules develop? One of the mechanisms
of action of methotrexate is through increase in adenosine
levels. Adenosine binds to both adenosine 1 receptors to
produce anti-inflammatory effect. Whereas binding to
adenosine 2 receptor on monocytes has been shown to
multinucleated giant cell formation and spindle shaped
transformation of monocytes, cells similar to that seen in
nodule formation.8 Histopathology of these nodules is
identical to rheumatoid nodules showing central zone of
necrosis surrounded by palisading monocytes and
multinucleated giant cells.9
MIAN is not unique to RA and has been reported in other
conditions like JIA,10 dermatomyositis2 and psoriatic arthritis11
as was seen in two of our patients.
The inactive disease status at the time of appearance of
MIAN in most of our patients and the benign nature of these
nodules suggests against the discontinuation of methotrexate
in all the patients of MIAN. However, the potential for fatality,2
should caution both the physicians and the patients to have
a close monitoring.
None of the two patients whose HLA typing was available
with us had HLA DR B*0401. However, HLA typing of more
patients is needed to discern the true genetic susceptibility
towards MIAN in Indian patients.
Ours is the first study of MIAN from India and we feel that
it is not uncommon and presents in a similar manner as in
Caucasians. Like in Caucasians, it has no association with
rheumatoid factor positivity, past history of nodules, disease
activity and cumulative dose and duration of methotrexate
therapy. Response to drugs like hydroxy-chloroquine, D-
Penicillamine or colchicine needs further study in Indian
patients.
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Announcement
The Department of Immunology, Sanjay Gandhi Post-graduate Institute of Medical Sciences, Lucknow will be
conducting the 'Vth National Autoantibody Workshop' from September 13-18, 2004. In addition one day
'Postgraduate clinics in Rheumatology' will be held on September 12.
For information please contact : Dr. Amita Aggarwal, Department of Immunology, SGPGIMS,
Lucknow 226 014. Fax : 0522-2668017; E_mail : amita@sgpgi.ac.in
